Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

Regeneron's Fianlimab Combination Misses Primary Endpoint in Melanoma Phase 3

Regeneron announced that its Phase 3 trial evaluating fianlimab (LAG-3 inhibitor) in combination with cemiplimab (PD-1 inhibitor) for first-line unresectable or metastatic melanoma did not achieve statistical significance for its primary endpoint of progression-free survival (PFS) compared to pembrolizumab monotherapy. While the high-dose combination showed a numeric improvement of 5.1 months in median PFS (11.5 months vs 6.4 months for pembrolizumab), the p-value was 0.0627. No new safety signals were identified. A separate head-to-head Phase 3 trial against Opdualag is ongoing.

• The Phase 3 trial of fianlimab and cemiplimab combination failed to reach statistical significance for its primary endpoint of progression-free survival (PFS) against pembrolizumab monotherapy in first-line unresectable or metastatic melanoma. However, the high-dose combination arm demonstrated a numeric improvement, with a median PFS of 11.5 months compared to 6.4 months for pembrolizumab, resulting in a Hazard Ratio of 0.845 (95% CI: 0.709, 1.008) and a p-value of 0.0627.
• The safety profile of the fianlimab combination was consistent with previous findings, with no new safety signals identified during the trial. Regeneron is continuing a separate Phase 3 head-to-head trial in the same patient population, comparing the high-dose fianlimab and cemiplimab combination directly against Opdualag (nivolumab and relatlimab-rmbw), indicating continued development in this therapeutic area despite the initial endpoint miss.
• The randomized, double-blind Phase 3 trial enrolled 1,546 patients aged 12 years or older with unresectable locally advanced or metastatic melanoma who had not received prior systemic treatment for advanced disease. Patients were randomized to receive either high-dose fianlimab (1600 mg) and cemiplimab (350 mg), low-dose fianlimab (400 mg) and cemiplimab (350 mg), placebo and pembrolizumab (200 mg), or placebo and cemiplimab (350 mg), all administered every 3 weeks.

Fianlimab + Cemiplimab Phase 3: Primary Endpoint Missed, Numeric PFS Gain

The Morpheus-Melanoma trial (NCT05116202) represents a significant advancement in neoadjuvant therapy for stage III resectable melanoma. This phase 1b/2 randomized umbrella study evaluated tobemstomig, an anti-PD-1/anti-LAG-3 bispecific antibody, both as monotherapy and in combination with tiragolumab (anti-TIGIT), against the established standard of nivolumab plus ipilimumab. Tobemstomig monotherapy demonstrated comparable pathological response rates to nivolumab plus ipilimumab (80.0% vs 77.3%) while showing substantially improved safety profile with only 2.5% experiencing grade 3 or higher treatment-related adverse events compared to 22.7% with the combination control arm.

The KEYNOTE-716 trial provided long-term follow-up data for pembrolizumab in completely resected stage IIB or IIC cutaneous melanoma, with 976 participants followed for a median of 52.8 months. The study demonstrated sustained clinical benefit with median recurrence-free survival not reached for pembrolizumab versus 59.2 months for placebo (HR 0.65, 95% CI 0.52-0.80). Notably, the 48-month recurrence-free survival was 68.7% with pembrolizumab versus 56.5% with placebo. Safety analysis revealed that immune-mediated severe skin reactions occurred in 3.3% of pembrolizumab-treated patients compared to 0.6% in the placebo group, though these events were generally manageable.

Real-world evidence from multiple studies further supports the clinical utility of immunotherapy in advanced melanoma. A German-Swiss multicenter study of 120 patients treated with anti-PD-1 plus lenvatinib after prior immunotherapy failure demonstrated an objective response rate of 23% and median overall survival of 10 months, with 21% experiencing grade ≥3 treatment-related adverse events. Comprehensive meta-analyses confirmed that PD-1 plus CTLA-4 combinations offer the most substantial therapeutic improvement with overall survival HR of 0.59, though accompanied by increased toxicity (grade ≥3 adverse events RR 2.14), while PD-1 plus LAG-3 combinations provide a more balanced efficacy-safety profile.

Addressing Unmet Needs in First-Line Metastatic Melanoma Treatment

Current treatment approaches for unresectable or metastatic melanoma face significant challenges despite recent therapeutic advances. While immune checkpoint inhibitors and targeted therapies have improved survival outcomes compared to traditional chemotherapy, substantial limitations persist that affect patient care and prognosis. These challenges span efficacy, safety, resistance mechanisms, and the need for personalized treatment approaches.

• Treatment resistance and limited durability: Not all patients respond to targeted therapy or immunotherapy, with many experiencing relapse after initial response, while BRAF/MEK inhibitors often result in rapid response but are hindered by high rates of disease relapse and progression

• Central nervous system metastases management: Developing effective treatments for CNS metastases remains a critical challenge, as melanoma patients with active brain metastases have largely been excluded from registration trials for currently approved targeted and immune therapies

• Lack of predictive biomarkers: No reliable predictors of immunotherapy activity and efficacy have been identified or validated, and biomarkers capable of predicting clinical efficacy, prognosis, and adverse events are needed for optimal patient selection

• Severe adverse events and treatment complications: Despite lower toxicity than cytotoxic agents, checkpoint inhibitors cause characteristic severe adverse events including pneumonia, endocrinopathy, and colitis, with combination therapies increasing adverse event incidence and treatment discontinuation

• Limited efficacy in specific patient populations: High percentages of metastatic melanoma patients still do not benefit from immune checkpoint inhibitors, particularly those requiring concurrent steroid therapy, and additional approaches are needed for rare subtypes including mucosal, acral, and uveal melanomas

• Suboptimal treatment sequencing guidance: Evidence-based guidance for optimal adjuvant therapy sequence remains limited, particularly in immunosuppressed patients with BRAF V600-mutant melanoma brain metastases where treatment urgency complicates management decisions

LAG-3/PD-1 Combination Faces Uphill Battle in First-Line Melanoma

The recent announcement regarding the Phase 3 trial of fianlimab and cemiplimab in first-line unresectable or metastatic melanoma marks a significant moment for the evolving immunotherapy landscape. While the combination showed a numeric improvement in progression-free survival compared to pembrolizumab monotherapy, the failure to reach statistical significance (p=0.0627) is a clear setback. This outcome underscores the formidable challenge of improving upon the established efficacy of PD-1 inhibitors in advanced melanoma, a field where agents like pembrolizumab have already set a high bar for patient outcomes.

The journey of immune checkpoint inhibitors has transformed melanoma treatment, with PD-1 monotherapy and combinations like nivolumab plus ipilimumab demonstrating durable responses and long-term survival. The LAG-3 pathway, targeted by fianlimab, represents a promising avenue for enhancing anti-tumor immunity, as evidenced by the approval of nivolumab plus relatlimab. However, this trial's results suggest that not all PD-1/LAG-3 combinations will yield the same level of benefit, particularly when benchmarked against a highly effective monotherapy.

For Regeneron, this outcome necessitates a strategic re-evaluation of fianlimab's first-line potential. The ongoing head-to-head trial against Opdualag (nivolumab plus relatlimab) now carries even greater weight. To carve out a meaningful market share, fianlimab plus cemiplimab will need to demonstrate either superior efficacy or a more favorable safety profile compared to the existing PD-1/LAG-3 combination. The risk remains that without a statistically significant advantage, the combination may struggle to gain traction in a crowded and highly competitive first-line setting. This event serves as a reminder that while the promise of combination immunotherapies is vast, the path to clinical and commercial success requires robust, undeniable evidence of improved patient outcomes. The industry continues its quest for truly synergistic regimens that can push the boundaries of survival for patients with advanced melanoma.